Rotavirus Vaccines Early Success, Remaining Questions

Source:NEJM Volume 360:1063-1065 March 12, 2009 Number 11

For abstract link here

Year of publication: 2009

Publication Type: Journal Article

Length of Publication: 3 page article

In a nutshell: In 2006, the results of pivotal clinical trials of two new rotavirus vaccines — RotaTeq (Merck) and Rotarix (GlaxoSmithKline) — were published, and high efficacy (85 to 98%) against severe rotavirus diarrhea was reported for both products.1,2 Perhaps even more important, neither vaccine was associated with intussusception, an adverse effect that had led to the withdrawal of another rotavirus vaccine — RotaShield, made by Wyeth–Lederle — from the U.S. market in 1999. The rapid resurgence of rotavirus vaccines after the abrupt and devastating setback associated with the withdrawal of RotaShield was remarkable, reflecting the commitment of the public health community . . .

Further dissemination: If you think anyone would benefit from receiving this posting or from subscribing to this blog please email them the link to this blog and suggest they sign up to the blogs email newsletter to stay up-to-date with new content.